FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4206992022> ?p ?o ?g. }

• W4206992022 endingPage "108558" @default.
• W4206992022 startingPage "108558" @default.
• W4206992022 abstract "We have recently reported the discovery of a series of oxazolidinone hydroxamic acid derivatives that are potent inhibitors of 5-lipoxygenase (5-LO) [arachidonate 5-lipoxygenase; EC 1.13.11.34]. We now report that one of the most active members of this series, compound PH-251, [(R)-N-((3-(3-fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl) methyl)-N-hydroxyoctanamide], also possesses a unique and strong ability to concurrently inhibit mast cell degranulation. PH-251 inhibited the biosynthesis of leukotriene C4 (LTC4), as well as degranulation of IgE/allergen-activated bone marrow-derived mouse mast cells (BMMC) in vitro. In contrast, zileuton (the prototype 5-LO inhibitor) inhibited leukotriene generation, but not degranulation. Consistent with its dual activity, compound PH-251 also significantly inhibited both the early and the late anaphylactic contractions of guinea pig lung parenchymal strip, whereas zileuton inhibited only the late (leukotriene-dependent) contractions. Comparative structure-activity analysis of PH-251 and its structural analogues showed that the anti-degranulation effect appeared to be dependent on the length of the straight-chain hydrocarbon substitution on the hydroxamic acid moiety. In the in vivo studies, PH-251 (3-30 mg/kg s.c.) strongly inhibited various components of zymosan-induced peritonitis - a typical non-allergic LT-dependent animal model of inflammation. In the mouse allergic asthma model, the compound significantly inhibited allergen-induced bronchial eosinophilic inflammation and airway hyper-responsiveness to inhaled methacholine. These results show that PH-251 is a unique dual inhibitor of 5-LO and mast cell degranulation, with in vivo activity in animal models of disease and may therefore offer potential advantages over single-target drugs in the treatment of asthma and other allergic and inflammatory diseases." @default.
• W4206992022 created "2022-01-26" @default.
• W4206992022 creator A5033040538 @default.
• W4206992022 creator A5041313393 @default.
• W4206992022 creator A5061746223 @default.
• W4206992022 creator A5065967997 @default.
• W4206992022 creator A5072543163 @default.
• W4206992022 date "2022-04-01" @default.
• W4206992022 modified "2023-10-14" @default.
• W4206992022 title "Anti-allergic, anti-asthmatic and anti-inflammatory effects of an oxazolidinone hydroxamic acid derivative (PH-251) – A novel dual inhibitor of 5-lipoxygenase and mast cell degranulation" @default.
• W4206992022 cites W1027996333 @default.
• W4206992022 cites W1483529759 @default.
• W4206992022 cites W1492698217 @default.
• W4206992022 cites W1965602820 @default.
• W4206992022 cites W1978767801 @default.
• W4206992022 cites W1982386486 @default.
• W4206992022 cites W1986462191 @default.
• W4206992022 cites W2012733287 @default.
• W4206992022 cites W2022254932 @default.
• W4206992022 cites W2076818664 @default.
• W4206992022 cites W2109954853 @default.
• W4206992022 cites W2137487999 @default.
• W4206992022 cites W2166132450 @default.
• W4206992022 cites W2282197705 @default.
• W4206992022 cites W2290501016 @default.
• W4206992022 cites W2328732682 @default.
• W4206992022 cites W2341080885 @default.
• W4206992022 cites W2626246102 @default.
• W4206992022 cites W2746532766 @default.
• W4206992022 cites W2762347804 @default.
• W4206992022 cites W2791242949 @default.
• W4206992022 cites W2899334068 @default.
• W4206992022 cites W2903788560 @default.
• W4206992022 cites W2912452740 @default.
• W4206992022 cites W2964027117 @default.
• W4206992022 cites W2975683151 @default.
• W4206992022 cites W3004029018 @default.
• W4206992022 cites W3041449817 @default.
• W4206992022 cites W3100906459 @default.
• W4206992022 doi "https://doi.org/10.1016/j.intimp.2022.108558" @default.
• W4206992022 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35091338" @default.
• W4206992022 hasPublicationYear "2022" @default.
• W4206992022 type Work @default.
• W4206992022 citedByCount "2" @default.
• W4206992022 countsByYear W42069920222022 @default.
• W4206992022 countsByYear W42069920222023 @default.
• W4206992022 crossrefType "journal-article" @default.
• W4206992022 hasAuthorship W4206992022A5033040538 @default.
• W4206992022 hasAuthorship W4206992022A5041313393 @default.
• W4206992022 hasAuthorship W4206992022A5061746223 @default.
• W4206992022 hasAuthorship W4206992022A5065967997 @default.
• W4206992022 hasAuthorship W4206992022A5072543163 @default.
• W4206992022 hasBestOaLocation W42069920221 @default.
• W4206992022 hasConcept C141105273 @default.
• W4206992022 hasConcept C150903083 @default.
• W4206992022 hasConcept C159654299 @default.
• W4206992022 hasConcept C170493617 @default.
• W4206992022 hasConcept C181199279 @default.
• W4206992022 hasConcept C185592680 @default.
• W4206992022 hasConcept C203014093 @default.
• W4206992022 hasConcept C203565725 @default.
• W4206992022 hasConcept C207001950 @default.
• W4206992022 hasConcept C2776042228 @default.
• W4206992022 hasConcept C2776452501 @default.
• W4206992022 hasConcept C2776914184 @default.
• W4206992022 hasConcept C2778078955 @default.
• W4206992022 hasConcept C2779543280 @default.
• W4206992022 hasConcept C2779726688 @default.
• W4206992022 hasConcept C2780769369 @default.
• W4206992022 hasConcept C2781370401 @default.
• W4206992022 hasConcept C49802076 @default.
• W4206992022 hasConcept C55493867 @default.
• W4206992022 hasConcept C71924100 @default.
• W4206992022 hasConcept C86803240 @default.
• W4206992022 hasConcept C90342290 @default.
• W4206992022 hasConcept C98274493 @default.
• W4206992022 hasConceptScore W4206992022C141105273 @default.
• W4206992022 hasConceptScore W4206992022C150903083 @default.
• W4206992022 hasConceptScore W4206992022C159654299 @default.
• W4206992022 hasConceptScore W4206992022C170493617 @default.
• W4206992022 hasConceptScore W4206992022C181199279 @default.
• W4206992022 hasConceptScore W4206992022C185592680 @default.
• W4206992022 hasConceptScore W4206992022C203014093 @default.
• W4206992022 hasConceptScore W4206992022C203565725 @default.
• W4206992022 hasConceptScore W4206992022C207001950 @default.
• W4206992022 hasConceptScore W4206992022C2776042228 @default.
• W4206992022 hasConceptScore W4206992022C2776452501 @default.
• W4206992022 hasConceptScore W4206992022C2776914184 @default.
• W4206992022 hasConceptScore W4206992022C2778078955 @default.
• W4206992022 hasConceptScore W4206992022C2779543280 @default.
• W4206992022 hasConceptScore W4206992022C2779726688 @default.
• W4206992022 hasConceptScore W4206992022C2780769369 @default.
• W4206992022 hasConceptScore W4206992022C2781370401 @default.
• W4206992022 hasConceptScore W4206992022C49802076 @default.
• W4206992022 hasConceptScore W4206992022C55493867 @default.
• W4206992022 hasConceptScore W4206992022C71924100 @default.
• W4206992022 hasConceptScore W4206992022C86803240 @default.
• W4206992022 hasConceptScore W4206992022C90342290 @default.

• next